BioMarin Pharmaceutical (NASDAQ:BMRN)

Biotechnology word cloud

Who Bucked the Short Interest Trend in Biotech Stocks?

24/7 Wall St. has tracked the short interest in leading biotech and emerging pharmaceutical stocks. Many biotech stocks pulled back in late March, and short sellers moved in on many ...
Read Full Story »
Bull and Bear

Top Analyst Upgrades and Downgrades: Arch Coal, BlackBerry, Himax, Palo Alto, Varonis and More

Stocks are caught in a tug-of-war, trying to decide if they need to pull back further or hit new highs again. Investors are looking for gains on the upside and ...
Read Full Story »
Biotechnology word cloud

Short Sellers Return to Biotech Stocks

24/7 Wall St. has tracked the short interest in leading biotech and emerging pharmaceutical stocks. After largely shying away in the previous period, short sellers returned to many of these ...
Read Full Story »
biotech

Cowen Top Biotech Stocks to Buy for 2014 With Huge Upside

Anybody that has been long the biotechnology sector for the past four years has had outstanding returns. Following four straight years of outperformance against the S&P 500, investor interest in ...
Read Full Story »
Pills

UBS Has Nine Biotech Buyout and Merger Candidates

After three years of solid outperformance, most firms on Wall Street that we cover remain very positive on biotechnology as a whole. The analysts at UBS are not only bullish ...
Read Full Story »
JPMorgan_logo

J.P. Morgan Top Biotechnology Stocks to Buy for 2014

Biotechnology was an incredible performer in 2013, outperforming the S&P 500 by a stunning 36%. The analysts at J.P. Morgan think that the huge outperformance may lessen but can stay ...
Read Full Story »
2014 in the box

Cowen Forecasts Top 10 Potential Biotech Surprises for 2014

All of the major firms on Wall Street we cover have prognostications and stock picks for 2014. The Cowen biotechnology team has a list of top 10 surprises that are ...
Read Full Story »
biotech

Top Biotechs Set to Win in the War on Cancer

Tuesday saw the wrap up of the 2013 European Society of Medical Oncology (ESMO) conference in Amsterdam, which featured key data from several of the companies covered by the biotech ...
Read Full Story »
biotech

Which Biotech Stocks Are Buyout Targets After Onyx Pharmaceutical Rejects Amgen?

On Friday after the market closed, biotech giant Amgen Inc. (NASDAQ: AMGN) made an unsolicited $120 per share bid for Onyx Pharmaceuticals Inc. (NASDAQ: ONXX) that was rejected. The company ...
Read Full Story »
biotech

PropThink Biotech Stocks With Big Upside Potential

The world of biotech investing is always a difficult one. Often a binary event, such as a U.S. Food and Drug Administration (FDA) approval or a life-saving capital raise is ...
Read Full Story »
Wall St Bull statue

Top Wall Street Analyst Upgrades: Arch Coal, Gap, BioMarin and More

Investors and traders seem to be constantly looking for fresh research ideas that will lead to higher income or more profits. 24/7 Wall St. reviews many research calls each day ...
Read Full Story »
131772836

Top Institutional Portfolio Stocks to Buy at Oppenheimer

Friday's nonfarm payroll number was a pleasant surprise. However, for real growth to return we need to consistently add 250,000 jobs per month. Our economy is sluggish at best, and ...
Read Full Story »
biotech

Top Biotech-Pharma Stock Ideas With Continued Big Upside (OREX, HALO, BAX, BMRN)

Much of the research coverage on Wall St. from the bulge bracket firms is concentrated on the most liquid, best known stocks from the S&P 500. These names are recognizable ...
Read Full Story »

BioMarin Drug Meets Endpoint and Will Seek FDA Approval

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is surging on news that a drug met its primary endpoint and that it will seek approval in early 2013. The company's Phase III study of GALNS is ...
Read Full Story »

Top Analyst Upgrades and Downgrades (AMZN, BNNY, ADSK, BBY, BMRN, BRCD, LLY, FNF, GTIV, THS)

These are the top analyst calls of upgrades, downgrades and initiations we have seen from Wall St. research calls this Monday morning. Amazon.com Inc. (NASDAQ: AMZN) reiterated Buy with $264 ...
Read Full Story »